EVOGENE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 239 ILa | -2.25% |
|
-3.36% | -20.28% |
| 23/05 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
| 23/05 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
| Sales 2024 * | 17M 6.32B 1.42B | Sales 2025 * | 31.5M 11.72B 2.62B | Capitalization | 33.32M 12.39B 2.78B |
|---|---|---|---|---|---|
| Net income 2024 * | -20M -7.44B -1.67B | Net income 2025 * | -17M -6.32B -1.42B | EV / Sales 2024 * | 1.96 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.06 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | -2.25% | ||
| 1 week | -3.36% | ||
| Current month | -13.44% | ||
| 1 month | -4.59% | ||
| 3 months | -17.59% | ||
| 6 months | -1.69% | ||
| Current year | -20.28% |
1 week
236.00
253.20
1 month
236.00298.90
Current year
231.20370.00
1 year
189.30610.40
3 years
189.301 212.00
5 years
189.303 350.00
10 years
189.305 794.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01/02/01 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 01/22/01 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/05/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 17/21/17 |
Sarit Firon
CHM | Chairman | 58 | 11/16/11 |
Leon Recanati
BRD | Director/Board Member | 76 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 239 | -2.25% | 56 754 |
| 17/24/17 | 244.5 | +0.45% | 23,734 |
| 16/24/16 | 243.4 | -1.58% | 24,917 |
| 13/24/13 | 247.3 | -3.21% | 40,549 |
| 10/24/10 | 255.5 | -1.01% | 15,974 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 18, 2024 at 07:22 pm IST
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 33.32M | |
| +34.92% | 52.85B | |
| -7.74% | 38.87B | |
| +35.40% | 38.24B | |
| -10.77% | 26.79B | |
| +11.77% | 26.16B | |
| -18.67% | 19.9B | |
| +35.82% | 13.18B | |
| +29.36% | 12.24B | |
| -3.07% | 11.79B |
- Stock Market
- Equities
- EVGN Stock
